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Background. Urinary lipoarabinomannan (LAM) has limited sensitivity for diagnosing active human immunodeficiency virus 
(HIV)-associated tuberculosis (TB) disease, but LAM screening at HIV diagnosis might identify adults with more severe clinical 
disease or greater risk of mortality.
Methods. We enrolled antiretroviral therapy-naive HIV-infected adults from 4 clinics in Durban. Nurses performed urine LAM 
testing using a rapid assay (Determine TB LAM) graded from low (1+) to high (≥3+) intensity. Urine LAM results were not used to 
guide anti-TB therapy. We assessed TB-related symptoms and obtained sputum for mycobacterial smear and culture. Participants 
were observed for 12 months, and we used multivariable Cox proportional hazard models to determine hazard ratios for all-cause 
mortality.
Results. Among 726 HIV-infected adults with median CD4 of 205 cells/mm3 (interquartile range, 79–350 cells/mm3), 93 (13%) 
were LAM positive and 89 (12%) participants died during the follow-up period. In multivariable analyses, urine LAM-positive 
participants had a mortality hazard ratio (MHR) of 3.58 (95% confidence interval [CI], 2.20–5.81) for all-cause mortality. Among 
participants with mycobacterial-confirmed TB, urine LAM-positivity had a 2.91 (95% CI, 1.26–6.73) MHR for all participants and a 
4.55 (95% CI, 1.71–12.1) MHR for participants with CD4 ≤100 cell/mm3. Participants with LAM-positive TB had significantly more 
clinical signs and symptoms of disease, compared with participants with LAM-negative TB disease.
Conclusions. Among HIV-infected adults, urinary LAM-positive patients had more clinical disease severity and a 3-fold 
increase in 12-month mortality compared with those who were LAM negative.
Keywords. HIV/AIDS; lipoarabinomannan (LAM); South Africa; tuberculosis; urine. 
Tuberculosis (TB) is the leading infectious cause of mortal-
ity worldwide and a leading cause of human immunodefi-
ciency virus (HIV)-related mortality [1, 2]. The World Health 
Organization (WHO)’s “End TB Strategy” seeks to end the TB 
epidemic (incidence <10 cases/100 000 people) by the year 2035 
[3]. The strategy relies on screening all HIV-infected persons 
for 4 TB-related symptoms: current cough, fever, night sweats, 
and weight loss [4, 5]. The WHO recommends that people liv-
ing with HIV be systematically screened for active TB at each 
visit to a health facility [5]. Those who have any TB-related 
symptom should undergo appropriate diagnostic testing with a 
test that has high diagnostic specificity, such as the Xpert MTB/
RIF assay [5].
Some HIV-infected people with active TB may not experi-
ence typical TB symptoms, which leads to poor accuracy of 
TB screening algorithms. A meta-analysis of 12 observational 
studies reported that the subjective symptom-based screening 
algorithm had a diagnostic sensitivity of 79% and specificity of 
50% among HIV-infected adults worldwide [6]. Furthermore, 
although symptom-based screening can improve early detec-
tion of active TB, symptom-based screening has not been 
demonstrated to directly impact health outcomes, compared 
with passive case finding [4]. Better screening “triage” tests are 
being evaluated [7, 8], and an alternative clinic-based approach 
could use a rapid diagnostic test that has better prognostic 
capacity.
Lipoarabinomannan (LAM), a glycolipid within the cell wall 
of TB, may be a useful pathogen biomarker to identify patients 
with active HIV-associated TB infections who have a greater 
risk of death [9]. In a recent meta-analysis, rapid LAM testing 
was associated with greater mortality risk, but these studies were 
predominantly among sick, hospitalized patients [10]. In several 
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clinic-based studies, a rapid LAM assay has demonstrated poor 
diagnostic sensitivity for use as a stand-alone TB screening test 
at HIV diagnosis [11–15], and the WHO recommended against 
using urine LAM as an ambulatory TB screening test among HIV-
infected persons [16]. However, because we have demonstrated 
that a rapid LAM assay can be easily performed by nurses in an 
ambulatory clinical setting [11], we sought to determine whether 
urine LAM positivity might identify adults with more severe clin-
ical disease or be a viable prognostic marker of mortality among 
newly diagnosed HIV-infected adults in a TB-endemic region. If 
urinary LAM positivity reflects greater disease severity or mortal-
ity risk, then LAM screening might be beneficial at HIV diagnosis 
to identify people who need accelerated anti-TB therapy initiation 
and/or more intensive clinical monitoring.
METHODS
Study Design and Participants
We conducted a prospective, clinic-based, cohort study by 
enrolling consecutive, newly diagnosed, antiretroviral therapy 
(ART)-naive HIV-infected adults in the ambulatory clinical 
areas of 2 hospitals and 2 municipal health centers in KwaZulu-
Natal, South Africa from October 2011 to January 2014 [17, 
18]. The study was designed to assess the diagnostic accuracy 
and prognostic value of point-of-care urinary LAM screening, 
regardless of TB-related symptoms, at the time of HIV diagno-
sis in an outpatient setting, and we have previously reported the 
diagnostic accuracy results [11, 12]. Eligible participants were 
adults (≥18  years) who presented to the clinic for voluntary 
HIV testing and counseling, not known to be pregnant, and 
not having received anti-TB therapy within the prior 3 months. 
Ethics committees of the 2 local hospitals (McCord Hospital 
and St. Mary’s Hospital) and Partners HealthCare in Boston 
(no. 2006-P-001379/40) approved the study, and all study par-
ticipants provided written informed consent. Participants were 
offered ART and TB treatment in accordance with local and 
South African Department of Health guidelines [19], and uri-
nary LAM results were not used to guide therapeutic decisions.
Procedures
Study nurses, who had advanced training in TB diagnosis, care, 
and treatment, collected demographic, socioeconomic, and 
clinical information, including TB-related symptoms at enroll-
ment. Participants were asked to provide a sputum sample, and 
those unable to provide an expectorated sample underwent 
induction with 3% nebulized hypertonic saline. Participants 
were then asked to provide a urine sample in a sterile container. 
Nurses tested urine samples using a rapid LAM assay and inter-
preted the result within 25–35 minutes in the ambulatory clini-
cal setting. Participants were offered baseline CD4 count testing 
and received chest radiography as clinically indicated. Urine 
LAM test results were blinded from clinicians and not used to 
guide therapeutic decisions. All participants were followed for 
12 months from study enrollment.
Sputum for Tuberculosis Testing
A certified technologist, who was blinded to clinical informa-
tion and urinary LAM results, performed sputum smear micros-
copy on decontaminated samples using both Ziehl-Neelson and 
Auramine stains. Before staining for acid-fast bacilli (AFB), spu-
tum samples were decontaminated with N-acetyl-l-cysteine and 
NaOH to a final concentration of 1.25% before being centrifuged 
at 3000 revolutions for 20 minutes and resuspended in 1 mL 7H9 
broth. Decontaminated sputum samples were inoculated into 
Bactec 960 mycobacterial growth indicator tubes (MGIT; BD, 
Franklin Lakes, NJ) and solid culture Middlebrook 7H11 agar 
medium, and TB was confirmed using niacin and nitrate testing.
Participants were considered smear acid-fast positive if either 
Ziehl-Neelson or Auramine stains were positive, and they were 
considered culture positive if TB was identified from either liq-
uid or solid culture media. Microbiologically confirmed TB was 
defined as having either positive sputum smear AFB micros-
copy or mycobacterial culture. Participants were considered to 
have evidence of active TB disease if they had either microbio-
logically confirmed TB or were started on anti-TB therapy for 
presumptive TB based on clinical judgment.
Urinary Lipoarabinomannan Testing
Urine specimens were considered LAM positive if colorimetric 
bands were visible at both the control and test lines. Halfway 
through the study, based on operational feedback, nurses began 
graded positive urine LAM results from low-band intensity 
(1+) to high-band intensity (5+), according to the manufac-
turer’s original reference card with 5 positive categories. Rapid 
LAM tests that did not have a positive control line were repeated 
using the same urine sample.
Before study commencement, a representative from Alere 
Inc. conducted a training session for study nurses to review 
procedures and interpretation of the Determine TB LAM assay 
(Alere Inc., Waltham, MA), and study nurses practiced until 
comfortable. During the study, regular oversight and obser-
vation of the nurses’ LAM testing procedures by the principal 
investigator and study coordinator ensured continued testing 
competence and proficiency. All urine LAM tests (manufac-
turer lot numbers 110512, 120215, and 120222)  and reagents 
were maintained in a sealed pouch and stored out of direct sun-
light at room temperature (15–26°C), as recommended.
The nurse performed 2 rapid urine LAM tests on each fresh 
urine specimen. However, our previous analyses found no sig-
nificant benefit with the second urine LAM test [12]. Therefore, 
we restricted these analyses to only the first urine LAM test 
result. Among the subgroup with graded LAM results, nurses 
were allowed to grade a test as a “faint” positive if a line was 
visible but not dark enough to be considered a 1+ grade. Our 
previous analyses found this interpretation to be a false-posi-
tive result when compared with sputum culture for pulmonary 
TB [12], so “faint” positive results were reclassified as a negative 
LAM test result for these analyses.
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Outcome
The primary outcome was all-cause mortality within 12 months 
after the baseline assessment. We used the South African 
National Death Registry to determine survival status and the 
date of death during the 12-month follow-up period, and all 
participants were linked to the Registry. Participants who sur-
vived the follow-up period were censored at 12  months and 
contributed to the final outcome ascertainment.
Statistical Analysis
We categorized patients into one of the following 3 groups: (1) no 
evidence of TB and urine LAM-negative; (2) evidence of TB by 
either sputum culture or presumptive TB by clinical judgment, 
but urine LAM-negative; or (3) urine LAM-positive. We used 
these discrete categories, because our objective was to deter-
mine whether LAM positivity identifies a subset of TB-infected 
patients who have a higher clinical severity of disease and a greater 
risk of mortality, which may represent an important clinical 
distinction. We used Cox proportional hazard models to deter-
mine the association between baseline LAM result and the time 
to death within the 12-month, follow-up period. We compared 
Kaplan-Meier survival curves within the 12-month, follow-up 
period using a log-rank test. We stratified analyses by partici-
pants with CD4  >200 cells/mm3, CD4 101–200 cells/mm [3], 
and ≤100 cells/mm3, because these categories have been pre-
viously used and form the basis of WHO recommendations 
[12, 16]. We performed separate Cox proportional hazard 
models to compare urine LAM-positive participants against 
urine LAM-negative participants among those with evidence 
of clinically active TB disease, among participants with micro-
biologically confirmed TB, and among participants who were 
started on anti-TB therapy. We evaluated the mortality hazard 
ratio (MHR) by urine LAM grade, which included a test for 
trend. We evaluated hazard mortality ratios by other screening 
modalities—presence of a cough, any TB-related symptom, and 
sputum AFB smear-positive. All multivariable survival analyses 
were adjusted by age, sex, education, and smoking status.
To evaluate LAM as a marker of clinical disease severity, we 
used Fisher’s exact test and t tests to compare demographic, 
clinical, laboratory, and treatment outcomes between LAM-
negative and LAM-positive adults, where appropriate. We 
conducted univariate and multivariable logistic regression 
analyses to compare participants with LAM-positive versus 
LAM-negative TB disease. We first conducted unadjusted lin-
ear regression models for each independent variable. Factors 
with P <  .2 were then included together in a single multivar-
iable model. Factors that were no longer significant at the 0.2 
level in the full multivariable model were removed one at a time. 
Finally, factors not selected based on the unadjusted analyses 
were included one at a time in the current multivariable model 
to assess their importance in adjusted analyses. We calculated 
95% confidence intervals (CIs), reported 2-tailed P values 
(α = 0.05), and used SAS 9.4 (Cary, NC).
RESULTS
Cohort Characteristics and Outcomes
We enrolled 796 newly diagnosed, ART-naive HIV-infected 
adults. After excluding 31 (4%) participants unable to provide 
a urine specimen and 39 (5%) participants who were receiv-
ing anti-TB therapy, our analyses included 726 HIV-infected 
adults (Table  1). Mean age was 34  years (standard deviation 
10 years), 59 (8%) participants reported a prior TB infection, 
and 169 (23%) participants were current smokers. Overall, each 
TB-related symptom was reported by 31%–38% of participants. 
Among the 627 (86%) participants who completed CD4 testing, 
the median CD4 count was 205 cells/mm3 (interquartile range, 
79–350 cells/mm3).
The observed prevalence of culture-confirmed pulmonary TB 
was 18% (95% CI, 15–21%). Ninety-three (13%) participants 
Table 1. Cohort Characteristics of ART-Naive HIV-Infected Adults
Characteristics
Mean ± SD or 
N (%)
Demographic and Education
 Age (years) 34 ± 10
 Male sex 385 (53)
 Completed high school 274 (38)
Clinical
 Prior TB infection 59 (8)
 Currently smoke tobacco 169 (23)
 Taking a diuretic medication 3 (<1)
TB-Related Symptoms
 Current cough 255 (35)
 Fever 227 (31)
 Night sweats 227 (31)
 Weight loss 277 (38)
 Having any of the above TB-related symptoms 449 (62)
CD4 Cell Count [median/IQR]/mm3 (N = 627) 205 [79–350]
 >200 cells/mm3 319 (51)
 101–200 cells/mm3 118 (19)
 ≤100 cells/mm3 190 (30)
Rapid Urine LAM Testing
 Positive by first rapid urine LAM test 93 (13)
 Positive by second rapid urine LAM test 103 (14)
 Positive by either rapid urine LAM test 106 (15)
Tuberculosis Test Results
 Sputum smear acid-fast bacilli positive 37 (5)
 Culture-confirmed pulmonary TB positive 123 (18)
 Microbiologically confirmed TB 139 (19)
TB Diagnosis by Category
 No evidence of TB and LAM-negative 504 (69)
 Evidence of TBa and LAM-negative 129 (18)
 LAM-positive 93 (13)
TB Therapy and Mortality
 Started anti-TB therapy 119 (16)
 Deaths during 12-month follow-up 89 (12)
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, inter-
quartile range; LAM, lipoarabinomannan; SD, standard deviation; TB, tuberculosis.
aEvidence of TB was defined as either microbiologically TB+ or being empirically stated on 
anti-TB therapy.
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were urinary LAM positive and 37 (5%) participants were sputum 
smear positive for AFB. Among those who were LAM-positive, 
38 (46%) participants had culture-confirmed pulmonary TB, 
and 34 of those 38 people initiated anti-TB therapy. Among 
those LAM-negative, 129 (18%) participants either had evidence 
of active TB or were initiated on anti-TB therapy. Eighty-nine 
(12%) participants died during the 12-month follow-up period.
Urinary Lipoarabinomannan and Mortality Risk Among Entire Cohort
Urine LAM-positive participants had a greater mortality hazard 
compared with LAM-negative participants without evidence of 
diagnosed or presumptive active TB disease (Table 2). The over-
all mortality rate during the 12-month, follow-up period was 
31.2% among those urine LAM positive, 14.0% among those 
with urine LAM-negative TB disease, and 8.3% among those 
without evidence of TB disease and LAM negative. In univariate 
analyses, participants who screened urine LAM positive had an 
MHR of 4.26 (95% CI, 2.65–6.84), compared with participants 
who were LAM negative and had no evidence of active TB dis-
ease. Urine LAM-positive participants with CD4 ≤100 cells/mm3 
also had a significantly greater mortality hazard, compared with 
participants with CD4 ≤100 cells/mm3 who were LAM negative 
and had no evidence of active TB disease.
In multivariable hazard models, participants who had either 
culture-confirmed or presumptive TB disease, but were urine 
LAM-negative, had a 1.54 (95% CI, 0.89–2.69) greater mortality 
hazard, compared with participants who were LAM negative and 
had no evidence of active TB disease (Table 2). Participants who 
had a positive LAM screening test had a 3.58 (95% CI, 2.20–5.81) 
greater hazard of mortality, compared with LAM-negative partic-
ipants who had no evidence of TB. Among those with CD4 ≤100 
cells/mm3, participants with a LAM-positive screening test had 
a 2.38 (95% CI, 1.34–4.21) greater mortality hazard, compared 
with those who were LAM negative and without evidence of TB.
The multivariable survival curve by TB category is shown 
for all participants (Figure 1A) and among immunosuppressed 
participants with CD4 ≤100 cells/mm3 (Figure 1B). Among all 
participants with censorship at 12 months, the median survival 
time was 8.2 (standard error [SE]  =  0.4) months for LAM-
positive participants, 10.5 (SE = 0.3) months for LAM-negative 
participants with evidence of TB, and 10.4 (SE = 0.1) months 
for LAM-negative participants with no evidence of active TB 
disease. Among participants with CD4  ≤100 cells/mm3, the 
median survival time was 7.4 (SE  =  0.6) months for LAM-
positive participants, 10.8 (SE = 0.4) months for LAM-negative 
participants with evidence of TB, and 9.6 (SE = 0.3) months for 
LAM-negative participants with no evidence of active TB dis-
ease. The differences between the 3 strata for all-cause mortality 
was highly significant for all participants (P < .0001) and when 
restricted to participants with CD4 ≤100 cells/mm3 (P < .0001).
Table 2. Hazard Ratio of Mortality by TB and Urinary LAM Status Among ART-Naive HIV-Infected South African Adults
Screening Test
Number of Deaths/ Number 
at Risk (%)
Unadjusted Models Adjusted Modelsa
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
All Participants
 No evidence of TB and LAM-negative 42/504 (8.3) Ref. — Ref. —
 Evidence of TBb and LAM-negative 18/129 (14.0) 1.73 (0.99–3.00) .05 1.54 (0.89–2.69) .13
 Urine LAM-positive 29/93 (31.2) 4.26 (2.65–6.84) <.0001 3.58 (2.20–5.81) <.0001
CD4 >200 cells/mm3
 No evidence of TB and LAM-negative 9/271 (3.3) Ref. — Ref. —
 Evidence of TBb and LAM-negative 3/30 (10.0) 3.17 (0.86–11.7) .08 3.46 (0.85–14.1) .08
 Urine LAM-positive 2/18 (11.1) 3.41 (0.74–15.8) .12 4.99 (0.98–25.4) .05
CD4 101–200 cells/mm3
 No evidence of TB and LAM-negative 6/69 (8.7) Ref. — Ref. —
 Evidence of TBb and LAM-negative 7/31 (22.6) 2.74 (0.92–8.16) .07 2.80 (0.91–8.57) .07
 Urine LAM-positive 4/18 (22.2) 2.80 (0.79–9.92) .11 2.72 (0.76–9.76) .13
CD4 ≤100 cells/mm3
 No evidence of TB and LAM-negative 27/164 (9.3) Ref. — Ref. —
 Evidence of TBb and LAM-negative 8/68 (11.8) 0.70 (0.32–1.53) .37 0.65 (0.29–1.43) .28
 Urine LAM-positive 23/57 (40.4) 2.80 (1.61–4.89) .0003 2.38 (1.34–4.21) .003
Participants With Microbiologically Confirmed TB
 Urine LAM-negative 14/99 (14.1) Ref. — Ref. —
 Urine LAM-positive 15/40 (37.5) 3.01 (1.45–6.23) .003 2.91 (1.26–6.73) .01
CD4 ≤100 cells/mm3
 Urine LAM-negative 10/71 (14.1) Ref. — Ref. —
 Urine LAM-positive 14/34 (41.2) 3.48 (1.54–7.84) .003 4.55 (1.71–12.1) .003
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; LAM, lipoarabinomannan; Ref., ; TB, tuberculosis.
aAdjusted by age, sex, education, and smoking status.
bEvidence of TB was defined as either microbiologically postive for TB or being started empirically on anti-TB therapy.
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Urinary Lipoarabinomannan and Mortality Risk Among All Tuberculosis 
(TB)-Positive and Microbiologically Confirmed TB
We then restricted our survival analyses to those who had either 
microbiological or clinical evidence of TB and to those with 
only microbiologically confirmed TB. Among participants with 
clinical or microbiological TB, the overall mortality rate was 
14.0% and 31.2% among those who screened urine LAM neg-
ative and positive, respectively. In a multivariable model, par-
ticipants with urine LAM-positive TB disease had a 2.33 (95% 
CI, 1.28–4.24) greater hazard of mortality, compared with urine 
LAM-negative TB disease. Among participants with CD4 ≤100 
cells/mm3, LAM-positive TB-infected adults had a 3.73 (95% 
CI, 1.65–8.42) greater risk of death in an adjusted model, com-
pared with LAM-negative TB-infected adults.
Urine LAM-positivity remained a significant predictor of mor-
tality when analyses were further restricted to the participants 
with microbiologically confirmed TB (Table 2). Overall, urine 
LAM-positive TB disease had a 3-fold greater hazard of death 
compared with urine LAM-negative TB disease. In a multivar-
iable analysis, urine LAM-positive participants with confirmed 
TB had an MHR of 2.91 (95% CI, 1.26–6.73), regardless of CD4 
count, and a 4.55 (95% CI, 1.71–12.1) greater mortality hazard 
when restricting analyses to those with CD4 ≤100 cells/mm3, 
compared with LAM-negative participants with confirmed TB.
Urine Lipoarabinomannan (LAM) and Mortality Risk by Grade of LAM Test
In separate subanalyses, participants with a higher LAM test 
grade had a greater hazard of mortality (Table  3). Overall, in 
a multivariable model, participants with a weak positive LAM 
result (1+) had a 2.57 (95% CI, 0.79–8.38) greater hazard of 
mortality, compared with LAM-negative participants who 
had no evidence of TB. Participants with a 2+ LAM grade and 
highly positive LAM result (≥3+) had a 3.41 (95% CI, 1.22–
9.57) and 5.02 (95% CI, 2.48–10.17) greater hazard of mortality, 
respectively. In separate multivariable models restricted to par-
ticipants with CD4 ≤200 cells/mm3 and CD4 ≤100 cells/mm3, a 
2+ LAM grade and highly positive LAM result (≥3+) remained 
significantly associated with a greater hazard of mortality. In all 
scenarios, a test for trend indicated that a higher grade of LAM 
positivity carried a significantly greater MHR.
Urinary Lipoarabinomannan in Comparison to Other Tuberculosis 
Screening Modalities
Among single screening assessments, participants with a cur-
rent cough, any TB-related symptom, and urine LAM positivity 
had a higher rate of mortality (Table 4). In separate multivaria-
ble models adjusted for age, sex, education, and smoking status, 
presence of any TB-related symptom and urine LAM positivity 
had a significant hazard ratio for mortality. Urine LAM positiv-
ity (≥1+) and urine LAM ≥2+ grade had hazard ratios of 3.18 
(95% CI, 2.02–5.00) and 3.34 (95% CI, 1.73–6.46) for mortality, 
and they were the highest hazard ratios among single screening 
assessments.
In subanalyses among TB-infected participants, presence of 
a cough and urine LAM positivity were each associated with a 
greater risk of mortality. In multivariable models, participants 
with presence of a cough had a 1.42 (95% CI, 0.83–2.41) greater 
hazard of mortality, whereas urinary LAM-positive participants 
had a 2.48 (95% CI, 1.55–3.98) greater hazard of mortality. 
When restricted to TB-infected participants with CD4  <200 
cells/mm3, only urine LAM screening was associated with a 
higher mortality risk (MHR = 2.29; 95% CI, 1.35–3.88). When 
including symptom screening and urinary LAM in the same 
multivariate model, urinary LAM remained a significant pre-
dictor of mortality.
Urinary Lipoarabinomannan by Anti-Tuberculosis Therapy Initiation
Among the 119 participants who initiated anti-TB therapy, 
LAM-positive participants had a 2.37 (95% CI, 0.91–6.14) 
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Figure 1. (A) Survival by tuberculosis (TB) category at baseline assessment for 
antiretroviral therapy (ART)-naive human immunodeficiency virus (HIV)-infected 
participants. (B) Survival by TB category at baseline assessment for ART-naive HIV-
infected participants with CD4 ≤100 cells/mm3. LAM, lipoarabinomannan.
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greater hazard of mortality compared with LAM-negative par-
ticipants. In a multivariable model, LAM-positive participants 
had a 2.44 (95% CI, 0.92–6.49) greater hazard of mortality. When 
restricting the analyses to the 95 participants with CD4 ≤200 
cells/mm3 who started anti-TB therapy, LAM-positive partici-
pants had a 2.29 (95% CI, 0.83–6.34) greater mortality hazard in 
a univariate model and 2.48 (95% CI, 0.85–7.20) greater mortal-
ity hazard in a multivariable model.
Urinary Lipoarabinomannan as a Biomarker of Severity of Clinical 
Disease
To examine urinary LAM as a biomarker of clinical disease sever-
ity, we compared clinical measures, laboratory results, and out-
comes between those with LAM-positive versus LAM-negative TB 
disease (Table 5). Participants with LAM-positive TB had signifi-
cantly more tachycardia (>100 heart beats/minute), lower systolic 
and diastolic blood pressures, more liquid, or solid positive TB cul-
ture result. The rate of TB treatment outcomes (failed, defaulted, or 
not completed treatment) was similar between the 2 groups.
In univariate logistic regression models, LAM-positive TB 
disease was associated with having more tachycardia, lower 
blood pressures, CD4 <100 cells/mm3, and having TB-culture 
positive disease, compared with LAM-negative TB disease 
(Table 6). In multivariable analyses, LAM-positive TB disease 
was most strongly associated with lower systolic blood pressure, 
having TB-culture positive disease, and having a current cough.
DISCUSSION
In this high TB-burden setting, ART-naive adults with a positive 
clinic-based urine LAM screening test had significantly greater 
risk of death within the 12  months after HIV diagnosis. The 
risk of death was greatest for adults with a CD4 ≤100 cells/mm3 
and among participants with highly positive (≥2+) urine LAM 
test result. In addition, urinary LAM-positive participants had 
more severe clinical signs and symptoms of disease. Urinary 
LAM testing was strongly associated with clinical disease sever-
ity and all-cause mortality, whereas symptom-based screening 
was not associated with mortality among adults with evidence 
of TB. These results suggest that LAM screening among ART-
naive adults at HIV diagnosis might identify immunocompro-
mised adults who have a greater risk of death and who might 
benefit from accelerated initiation of anti-TB therapy and/or 
more intensive clinical monitoring.
Current WHO guidelines recommend diagnostic urine LAM 
testing in sick, HIV-infected, hospitalized patients, and do not 
recommend urinary LAM screening in ambulatory clinics due 
to limited supportive evidence [16]. In a recent hospital-based, 
Table 3. Hazard Ratio of Mortality by Urinary LAM Grade Among ART-Naive HIV-Infected South African Adults
Screening Test
Number of Deaths/ 
Number at Risk (%)
Unadjusted Models Adjusted Modelsa
Hazard Ratio  
(95% CI) P Value P Value for Trend
Hazard Ratio  
(95% CI) P Value P Value for Trend
All Participants <.0001 <.0001
 No evidence of TB and 
LAM-negative
42/504 (8.3) Ref. — Ref. —
 Evidence of TB and 
LAM-negative
18/129 (14.0) 1.71 (0.99–2.98) .06 1.54 (0.88–2.68) .13
 Urine LAM 1+ grade 3/14 (21.4) 2.74 (0.85–8.83) .09 2.57 (0.79–8.38) .12
 Urine LAM 2+ grade 4/13 (30.8) 4.12 (1.48–11.5) .007 3.41 (1.22–9.57) .02
 Urine LAM ≥3+ grade 10/23 (43.5) 6.88 (3.45–13.7) <.0001 5.02 (2.48–10.2) <.0001
Participants with CD4 ≤200 
cells/mm3
<.0001 .0005
 No evidence of TB and 
LAM-negative
33/233 (14.2) Ref. — Ref. —
 Evidence of TB and 
LAM-negative
15/100 (15.0) 1.06 (0.57–1.94) .86 0.99 (0.53–1.83) .96
 Urine LAM 1+ grade 3/12 (25.0) 1.83 (0.56–5.95) .32 1.74 (0.53–5.72) .36
 Urine LAM 2+ grade 4/10 (40.0) 3.17 (1.12–8.95) .03 2.71 (0.95–7.71) .06
 Urine LAM ≥3+ grade 9/19 (47.4) 4.51 (2.15–9.43) <.0001 3.61 (1.69–7.71) .0009
Participants With CD4 ≤100 
cells/mm3
.0003 .003
 No evidence of TB and 
LAM-negative
27/164 (16.5) Ref. — Ref. —
 Evidence of TB and 
LAM-negative
8/69 (11.6) 0.69 (0.31–1.51) .35 0.65 (0.29–1.43) .31
 Urine LAM 1+ grade 3/8 (37.5) 2.45 (0.74–8.09) .13 2.10 (0.63–7.05) .21
 Urine LAM 2+ grade 4/8 (50.0) 3.51 (1.23–10.0) .02 2.96 (1.01–8.70) .05
 Urine LAM ≥3+ grade 8/17 (47.1) 3.70 (1.68–8.14) .001 3.04 (1.34–6.91) .008
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; LAM, lipoarabinomannan; Ref., ; TB, tuberculosis.
aAdjusted by age, sex, education, and smoking status.
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randomized, controlled trial, urine LAM testing performed 
by trained research nurses and used to expedite initiation 
of anti-TB therapy led to a relative risk reduction of 17% for 
8-week all-cause mortality among HIV-infected adults with at 
least 1 TB-related symptom [20]. Several other hospital-based 
studies have demonstrated that urinary LAM testing can be 
predictive of mortality [21–24]. One combined hospital and 
outpatient participant study used fresh urine samples to predict 
mortality in Ghana [14]. Thus far, 2 smaller outpatient studies 
have used frozen urine samples tested in a laboratory setting to 
assess mortality risk, and both studies reported higher mortality 
rates with 3–6 months follow-up among LAM-positive partici-
pants [15, 25]. To our knowledge, our study represents the larg-
est longitudinal study of nurses performing real-time urinary 
LAM testing on fresh urine samples in outpatient ambulatory 
clinics with a direct association to clinical disease severity and 
having more than 6 months of participant follow-up.
In clinical settings, the accuracy of symptom-based screen-
ing to identify HIV-associated active TB disease has been 
poor. A  meta-analysis of 12 studies, only 3 of which were 
conducted in a high TB-burden setting (>10% prevalence), 
found symptom-based TB screening missed nearly one quar-
ter of active TB cases [6]. Inaccurate symptom-based screening 
among HIV-infected adults can lead to treatment delays, inad-
equate provision of isoniazid preventive therapy and overpre-
scribing of empiric TB therapy, and high loss to follow-up rates 
[1, 5]. Consequently, a WHO TB diagnostic group identified a 
screening test and algorithm as one of its highest priorities [7].
In our study, the current urine LAM assay predicted all-cause 
mortality at initial HIV diagnosis, which may be useful as a 
prognostic biomarker. The majority of the deaths in our cohort 
occurred within the first 3 months, which reflects a period of 
high risk for a vulnerable group. We have previously shown 
the urine LAM assay to be associated with more severe disease 
states and predict longer-term outcomes among patients who 
have completed the intensive 2-month period of initial anti-TB 
therapy [26, 27]. Together, these findings suggest that urine 
LAM-positive patients with a greater risk of mortality may have 
had a higher bacillary burden of TB. When compared with 
existing screening modalities for HIV-associated TB disease, 
urinary LAM screening outperformed symptom-based screen-
ing and AFB smear microscopy.
Table 4. Hazard Ratio of Mortality by Tuberculosis Screening Method Among Newly Diagnosed HIV-Infected South African Adults
Screening Test
Number of Deaths/ Number 
at Risk (%)
Unadjusted Models Adjusted Modelsa
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
All Participants
 Absence of Cough 46/471 (9.8) Ref. — Ref. —
 Presence of Cough 43/255 (16.9) 1.80 (1.18–2.72) .006 1.68 (1.10–2.55) .02
 No TB-related symptoms 17/277 (6.1) Ref. — Ref. —
 Any TB-related symptom 72/449 (16.0) 2.76 (1.63–4.68) .0002 2.41 (1.41–4.12) .001
 Sputum AFB smear-negative 75/650 (11.5) Ref. — Ref. —
 Sputum AFB smear-positive 6/37 (16.2) 1.43 (062-3.29) .40 1.22 (0.53–2.82) .64
 Urine LAM-negative 60/632 (9.5) Ref. — Ref. —
 Urine LAM-positive 29/93 (31.2) 3.72 (2.39–5.79) <.0001 3.18 (2.02–5.00) <.0001
 Urine LAM <2+ grade 30/313 (9.6) Ref. — Ref. —
 Urine LAM ≥2+ grade 14/36 (38.9) 4.74 (2.51–8.95) <.0001 3.34 (1.73–6.46) .0003
Participants With Evidence of TBb
 Absence of Cough 31/90 (34.4) Ref. — Ref. —
 Presence of Cough 44/85 (51.8) 1.82 (1.14–2.89) .01 1.67 (1.04–2.69) .03
 No TB-related symptoms 16/39 (41.0) Ref. — Ref. —
 Any TB-related symptom 59/136 (43.4) 1.22 (0.70–2.13) .47 1.07 (0.61–1.88) .82
 Urine LAM-negative 42/124 (33.9) Ref. — Ref. —
 Urine LAM-positive 33/51 (64.7) 2.51 (1.58–4.00) <.0001 2.48 (1.55–3.98) .0002
Participants With Evidence of TBb 
and CD4 <200/mm3
 Absence of Cough 25/64 (39.1) Ref. — Ref. —
 Presence of Cough 36/66 (54.6) 1.63 (0.97–2.73) .06 1.42 (0.83–2.41) .20
 No TB-related symptoms 11/25 (44.0) Ref. — Ref. —
 Any TB-related symptom 50/105 (47.6) 1.22 (0.64–2.35) .55 1.09 (0.56–2.12) .81
 Urine LAM-negative 33/87 (37.9) Ref. — Ref. —
 Urine LAM-positive 28/43 (65.1) 2.45 (1.47–4.10) .0006 2.29 (1.35–3.88) .002
Abbreviations: AFB, acid-fast bacilli; CI, confidence interval; HIV, human immunodeficiency virus; LAM, lipoarabinomannan; Ref., ; TB, tuberculosis.
aAdjusted by age, sex, education, and smoking status.
bEvidence of TB was defined as either microbiologically TB+ being empirically stated on anti-TB therapy.
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One prospective clinic-based study, the TB Fast Track study, 
evaluated urinary LAM testing as a triage tool in combination 
with TB-symptom screening, body mass index (BMI), and 
hemoglobin measurement [28, 29]. The study found no over-
all difference in mortality, which may have been due to the low 
sensitivity of urine LAM testing, and poor specificity of BMI 
and hemoglobin testing, to identify active TB disease. Because 
the LAM assay has inadequate sensitivity as a stand-alone 
screening test [11–13], several groups are working to develop 
a more sensitive LAM assay. One promising approach using 
high-avidity monoclonal antibodies reported a 50-fold increase 
in LAM detection and 93% diagnostic sensitivity of urine LAM 
testing in an Ethiopian cohort [30].
Our study had several strengths and limitations. Primary 
strengths were evaluating the urine LAM assay when used by 
trained nurses in ambulatory settings, which is similar to a 
real-world application, assessing both liquid and solid myco-
bacterial culture, enrolling participants on the day of HIV 
diagnosis and before ART initiation, assessing urine LAM 
among adults with a range of CD4 counts, and adjusting mul-
tivariable models for tobacco smoking and age, both of which 
influence TB outcomes. Primary limitations included using 
an observational study design, only grading half of the LAM 
test strips, as well as not evaluating participants for diabetes, 
low BMI, or alcohol dependence, which can also influence 
TB-related mortality. We also excluded participants who were 
unable to provide an expectorated or induced sputum sam-
ple, which could have biased the results. Although we were 
not able to ascertain the cause of death for participants, most 
deaths occurred within the first 3  months of LAM testing, 
Table 5. Characteristics Between LAM-Negative and LAM-Positive HIV-
Associated Tuberculosis (N = 194)
Characteristics
LAM-Negative TB 
(N = 138)
LAM-Positive 
TB (N = 56)
P 
Value
Mean ± SD or 
N (%)
Mean ± SD or 
N (%)
Demographic and Education
 Age (years) 35.3 ± 10.4 34.0 ± 7.5 .30
 Male sex 83 (60.1) 34 (60.7) 1.0
 Completed high school 50 (36.5) 15 (26.8) .24
Clinical
 Prior TB infection 9 (6.5) 5 (8.9) .55
 Currently smoke tobacco 32 (23.2) 8 (14.3) .24
 Body temperature 36.5 ± 1.2 36.5 ± 1.5 .77
 Fever (temperature >38.3°C) 8 (9.4) 5 (10.2) 1.0
 Heart rate 97.7 ± 22.9 115.2 ± 26.0 .0002
 Tachycardia (>100 heart beats/
minute)
39 (44.8) 32 (65.3) .03
 Systolic blood pressure 113.5 ± 16.0 104.7 ± 21.0 .01
 Diastolic blood pressure 73.2 ± 16.3 68.3 ± 12.3 .06
TB-Related Symptoms
 Current cough 60 (43.5) 32 (57.1) .11
 Fever 58 (42.0) 23 (41.1) 1.0
 Night sweats 59 (42.8) 28 (50.0) .43
 Weight loss 75 (54.4) 30 (53.6) 1.0
 Having any of 4 TB-related 
symptoms
104 (75.4) 46 (82.1) .35
 Having ≥2 TB-related 
symptoms
72 (52.2) 36 (64.3) .15
CD4 Cell Count
 Median [IQR] CD4 cells/mm3 115 [48–227] 61 [20–146] .002
 Low CD4 (<100 cells/mm3) 58 (45.3) 36 (66.7) .01
Sputum AFB Microscopy Results
 AFB negative 106 (80.9) 41 (77.4) .37
 AFB positive with “scant” 
or 1+
20 (15.3) 6 (11.3)
 AFB positive with ≥2+ 5 (3.8) 6 (11.3)
Sputum TB Culture Results
 Liquid culture (MGIT) positive 78 (60.9) 38 (74.5) .09
 Solid culture positive 42 (32.1) 33 (64.7) .0002
 Either culture positive 82 (62.6) 41 (80.4) .02
Treatment Outcomes
 Failed, defaulted, or not com-
pleted treatment
39 (47.6) 21 (56.8) .35
 Death during 12-month fol-
low-up period
19 (13.8) 19 (33.9) .001
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; LAM, lipo-
arabinomannan; SD, standard deviation; TB, tuberculosis.
Table 6. Univariate and Multivariable Logistic Regression of Risk Factors 
for LAM-Positive HIV-Associated TB, Compared With LAM-Negative HIV-
Associated TB (N = 194)
Characteristics
Univariate Odds 
Ratio (95% CI)
P 
Value
Multivariate Odds 
Ratio (95% CI)
P 
Value
Demographic and 
Education
 Age (years) 0.98 (0.95–1.02) .37 — —
 Male sex 1.02 (0.54–1.93) .94 — —
 Completed high 
school
0.64 (0.32–1.26) .20 — —
Clinical
 Currently smoke 
tobacco
0.55 (0.24–1.29) .17 — —
 Tachycardia (>100 
beats/minute)
2.32 (1.12–4.78) .02 1.85 (0.79–4.33) .16
 Systolic blood  
pressure (mmHg)
0.97 (0.95–0.99) .01 0.97 (0.95–0.99) .006
 Diastolic blood  
pressure (mmHg)
0.98 (0.95–1.00) .08 — —
TB-Related Symptoms
 Current cough 1.73 (0.93–3.25) .09 2.33 (1.01–5.39) .05
 Having any of 4 
TB-related 
symptoms
1.50 (0.69–3.30) .31 — —
 Having ≥2 TB-related 
symptoms
1.65 (0.87–3.13) .13 — —
CD4 Cell Count
 Low CD4  
(<100 cells/mm3)
2.41 (1.24–4.69) .009 — —
TB Testing Results
 Sputum smear acid-
fast bacilli positive
1.24 (0.57–2.70) .59 — —
 TB culture positive 2.45 (1.13–5.33) .02 2.71 (1.05–7.00) .04
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; LAM, lipo-
arabinomannan; TB, tuberculosis.
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suggesting that mortality was related to active HIV-associated 
TB disease.
CONCLUSIONS
In conclusion, clinic-based urine LAM screening predicted mor-
tality among ART-naive HIV-infected adults, which may have 
been due to detecting greater severity of clinical disease. A pro-
spective randomized clinical trial is required to determine whether 
clinic-based urine LAM screening with accelerated anti-TB ther-
apy can reduce mortality rates among HIV-infected adults in 
TB-endemic regions, particularly if a highly sensitive, second-gen-
eration, point-of-care urinary LAM assay becomes available.
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